Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for clozapine-refractory schizophrenia
ACTRN12622001112752Phase 2Terminated
- Sponsor
- The University of Queensland
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia and schizoaffective disorder comparing Cannabidiol adjunctive treatment with Placebo adjunctive treatment (2 arms). Primary endpoint: Change in PANSS positive score at week 12. Started Jun 2023; status: terminated.
02
Drugs
cannabidiol
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on ACTRN12622001112752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001112752.